{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:45:08Z","timestamp":1788306308083,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism. The aim was to assess the prevalence of clinically significant hypopituitarism a minimum of 2\u00a0years following radioisotope therapy for metastatic NET. This was a multicentre study (Australia and New Zealand). Sixty\u2010six patients with unresectable NETs were included\u201334 had received PRRT and 32 comparison patients. Median follow\u2010up after PRRT was 68\u00a0months. Male hypogonadism was the most common hormonal abnormality (16 of 38 men [42%]) from the total cohort. Of these, seven men had primary hypogonadism (five from PRRT group) and nine had secondary hypogonadism (six in PRRT group). There was no difference in either male hypogonadism or other hormonal dysfunction between patients who had received PRRT and those that had not. Patients who have received PRRT out to 68\u00a0months following treatment do not show concerning hypopituitarism although there may be the suggestion of growth hormone deficiency developing. However, hypogonadism is common in men with NETs so the gonadal axis should be assessed in men with suggestive symptoms as the treatment of testosterone deficiency may improve the quality of life.<\/jats:p>","DOI":"10.1002\/cam4.4345","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T04:08:26Z","timestamp":1635221306000},"page":"8405-8411","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-2300","authenticated-orcid":false,"given":"Marianne S.","family":"Elston","sequence":"first","affiliation":[{"name":"Waikato Clinical Campus University of Auckland Hamilton New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Love","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Royal Brisbane and Women's Hospital Herston, Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Kevat","sequence":"additional","affiliation":[{"name":"Monash Health Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Carroll","sequence":"additional","affiliation":[{"name":"Endocrinology Unit Capital &amp; Coast Health Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Rong","family":"Siow","sequence":"additional","affiliation":[{"name":"Monash Health Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Pattison","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dunedin School of Medicine University of Otago Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Boyle","sequence":"additional","affiliation":[{"name":"Waikato Clinical Campus University of Auckland Hamilton New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[{"name":"Monash Health Victoria Australia"},{"name":"Monash University Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Strickland","sequence":"additional","affiliation":[{"name":"Monash Health Victoria Australia"},{"name":"Monash University Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wyld","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Royal Brisbane and Women's Hospital Herston, Brisbane Queensland Australia"},{"name":"Faculty of Medicine University of Queensland Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gauci","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ransom","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(94)00956-2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.4.1386"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1314859"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.136.11.5232"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.136.11.5224"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04006-X"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet1051"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30053-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1525"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.066"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1151-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000507761","article-title":"Pituitary function after high\u2010dose 177Lu\u2010DOTATATE therapy and long\u2010term follow\u2010up","volume":"111","author":"Sundlov A","year":"2021","journal-title":"Neuroendocrinology"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2020.03.004"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000178754"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00229"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2019-0405"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T16:02:13Z","timestamp":1692979333000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":17,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/cam4.4345"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4345","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"2021-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}